摘要目的 探究孟鲁司特联合布地奈德治疗小儿咳嗽变异性哮喘的疗效,为临床提供指导.方法 选择2015年3月至2017年3月阳谷县人民医院90例小儿咳嗽变异性哮喘患儿作为研究对象,采用随机数字表法将90例患儿分为观察组(45例,应用孟鲁司特联合布地奈德治疗)、对照组(45例,应用布地奈德联合硫酸沙丁胺醇治疗).均随访3个月,研究对比观察组和对照组患儿的疗效、咳嗽缓解时间、咳嗽消失时间、不良反应发生率及复发率.结果 观察组患儿总有效率(95.56％)相比对照组(77.78％)明显更高(P＜0.05);观察组患儿咳嗽缓解时间[(7.79±3.23)d]、咳嗽消失时间[(10.78±2.36)d]相比对照组[(9.16±2.23)d、(12.24 ±2.78)d]明显更短(P＜0.05);观察组患儿不良反应发生率(2.22％)和对照组(6.67％)差异无统计学意义(P＞0.05),但观察组患儿复发率(4.44％)相比对照组(17.78％)明显更低(P＜0.05).结论 孟鲁司特联合布地奈德治疗小儿咳嗽变异性哮喘切实可行,有助于减少复发.

abstractsObjective To explore the curative effect of montelukast combined with budesonide in the treatment of cough variant asthma in children,to provide guidance for clinical practice.Methods From March 2015 to March 2017,90 children with cough variant asthma in the People's Hospital of Yanggu County were randomly divided into observation group(n =45) and control group(n =45) according to the digital table.The observation group was given budesonide combined with montelukast,while the control group was given budesonide combined with salbutamol sulfate.All patients were followed up for 3 months.The curative effect,cough relief time,cough disappearance time,incidence rate of adverse reaction and recurrence rate were compared between the two groups.Results The total effective rate of the observation group(95.56％) was significantly higher than 77.78％ of the control group(P ＜ 0.05).The cough relief time[(7.79 ± 3.23)d] and the cough disappearance time [(10.78 ± 2.36)d] in the observation group were significantly shorter than those in the control group [(9.16 ± 2.23) d,(12.24 ± 2.78) d] (all P ＜ 0.05).The incidence rate of adverse reactions of the observation group was 2.22％,which of the control group was 6.67％,there was no statistically significant difference between the two groups (P ＞ 0.05).The recurrence rate of the observation group (4.44％) was significantly lower than 17.78％ of the control group(P ＜ 0.05).Conclusion It is feasible to treat cough variant asthma in children with montelukast combined with budesonide,and it is helpful to reduce recurrence.